USA: Fluor Awarded Contract by Novo Nordisk $ 2 Billion Diabetes API Manufacturing Facility to Be Built

Editor: Alexander Stark

Fluor Corporation has been awarded an engineering, procurement, construction and construction management contract by Novo Nordisk for its new $ 2 billion diabetes Active Pharmaceutical Ingredient (API) manufacturing facility in Clayton, North Carolina.

Related Companies

Fluor to design and build $2 billion diabetes API manufacturing facility for Novo Nordisk in North Carolina
Fluor to design and build $2 billion diabetes API manufacturing facility for Novo Nordisk in North Carolina
(Source: Fluor Corporation)

Irving/USA — Fluor has been providing basic design services since Novo Nordisk announced plans for the new facility in August 2015 and now will be executing the full scope of work. Nearly 2,500 craft employees and subcontractor jobs are expected at peak construction with about 700 new jobs at the facility when it is completed. Construction is expected to be completed in mid-2019.

“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business. “This project is the single largest life sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”

“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry and ability to deliver the full scope of work,” said Morten Nielsen, senior vice president, Novo Nordisk, and responsible for the construction of the new facility. “We look forward to continued strong cooperation for the success of this project.”

(ID:44440753)